Millie: Search Results

Following media reports of internal documents indicating company knowledge of the dangers of their powder, thousands of plaintiffs now accuse J&J of knowing about the potential cancer risks.

465M award in Okla. opioid case is appealed by J&J.

Janssen (J&J's pharmaceutical division) did not cause the opioid crisis in Oklahoma, and neither the facts nor the law support this outcome,” said Michael Ullmann, executive vice president, general counsel, J&J. In its official petition, J&J has built on its case, listing 39 grounds for appeal ...

Frinzi previously led Abbott Medical Optics, including its cataract lens replacement, laser refractive surgery and consumer eye health businesses, before they were acquired by J&J for $4.325 billion in 2016.

According to J&J, the subcommittee had rejected the company’s offers to send a talc testing expert or a J&J executive in charge of consumer products as it says that Gorsky is not an expert in the subject of the hearing ...

In a response to Reuters, a J&J spokesman said the company “respectfully declined” the invitation as Gorsky isn’t “an expert in the stated subject of the hearing.

J&J’s CAR-T candidate – JNJ-4528 – impressed at the conference, as well as at the FDA, so much so that the drug has been granted a breakthrough therapy designation in previously treated multiple myeloma patients.

As per the terms of the deal, XBiotech could receive additional payments on top of the $750m sum if J&J decides to pursue bermekimab in indications other than dermatology.

The Maharashtra Food and Drug Administration (FDA) has forwarded applications of at least 50 patients for compensation after they underwent hip implants manufactured by pharmaceutical giant Johnson & Johnson (J&J) and suffered side effects.

J&J spokesman Ernie Knewitz said that the subcommittee had rejected the company's offers to send a talc testing expert or a J&J executive in charge of consumer products.

Johnson & Johnson Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmeti.

In a phase 3 study of previously untreated myeloma patients not eligible for stem cell transplants, adding Darzalex (daratumumab) to a combination of melphalan, prednisone and Takeda’s Velcade cut the risk of death by 40%, J&J’s Janssen unit said at the American Society of Hematology annual meeting.

ArQule stock rocketed more than 100% on Monday after Dow Jones stock Merck pledged to buy it for $2.7 billion. The biotech company is working on precision medicine in cancer treatment. .

8-K.

The B cell maturation antigen directed CAR-T therapy is being developed by Janssen, a subsidiary of J&J, as a potential treatment for relapsed or refractory multiple myeloma (r/rMM.

Amgen AMGN announced that the FDA has granted approval to its biosimilar version of Johnson and Johnson JNJ/Merck’s MRK blockbuster immunology medicine, Remicade (infliximab.

J&J aims to help Rwanda buffer Ebola's advance with 200,000 vaccine doses.

J&J's CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study. The treatment, which also shrank tumors in all 29 of the patients, kept cancer at bay in 93% of patients six months after dosing.

A CAR-T therapy being developed by Johnson & Johnson showed very effective, albeit preliminary results in a new clinical trial involving multiple myeloma patients.

Mentions

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities

Sources

Strategic Scenarios

Trends